Medicare Enrolled
Dr. Simon Badin, M.D.
Hematology & Oncology · Jersey City, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Badin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Badin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Badin
Dr. Simon Badin is a hematology & oncology specialist in Jersey City, NJ, with 17 years of NPI registration. Based on federal Medicare data, Dr. Badin performed 53,786 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Badin received a total of $5,683 from 55 pharmaceutical and/or device companies across 313 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Badin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years of NPI registration
▲ Top 20% volume in NJ
$5,683 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗53,786
Medicare services
Top 20% in NJ for hematology & oncology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
26,839 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 7,201 | $18 | $45 |
| Anti-nausea injection (ondansetron/Zofran) | 5,255 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,240 | $6 | $15 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,499 | $0 | $1 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
719 | $73 | $139 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
640 | $102 | $131 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
610 | $2 | $107 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
570 | $11 | $34 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
522 | $26 | $72 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
509 | $1 | $4 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
476 | $26 | $70 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
439 | $18 | $44 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
436 | $1 | $4 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
418 | $48 | $97 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
370 | $57 | $151 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
259 | $12 | $43 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
253 | $111 | $300 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
236 | $14 | $54 |
| D5W intravenous infusion, 1000 cc Administration of 1000 cc of 5% dextrose in water through a vein. |
198 | $3 | $7 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
197 | $115 | $273 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
196 | $68 | $160 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
181 | $1 | $4 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
159 | $58 | $134 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
111 | $109 | $228 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
86 | $8 | $10 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
58 | $67 | $169 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
47 | $2 | $6 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $148 | $450 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
18 | $1 | $5 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $135 | $366 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
5.3% high complexity
87.9% medium
6.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,683
Total received (2018-2024)
Avg $812/year across 7 years
Top 39% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
313
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$137
2023
$600
2022
$1,265
2021
$1,280
2020
$1,006
2019
$794
2018
$602
Payments by company (2024)
Tempus AI, Inc
$75
GlaxoSmithKline, LLC.
$34
Gilead Sciences, Inc.
$14
Janssen Biotech, Inc.
$14
Top 3 companies account for 90.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$655
E.R. Squibb & Sons, L.L.C.
$589
Merck Sharp & Dohme Corporation
$539
AstraZeneca Pharmaceuticals LP
$536
Novo Nordisk Inc
$279
Janssen Biotech, Inc.
$247
Amgen Inc.
$237
GlaxoSmithKline, LLC.
$200
Incyte Corporation
$189
NOVARTIS PHARMACEUTICALS CORPORATION
$183
PFIZER INC.
$168
Celgene Corporation
$147
Bayer HealthCare Pharmaceuticals Inc.
$137
Exelixis Inc.
$120
Boehringer Ingelheim Pharmaceuticals, Inc.
$96
Genentech USA, Inc.
$92
GE HealthCare
$82
Lilly USA, LLC
$79
Tempus AI, Inc
$75
Astellas Pharma US Inc
$72
Gilead Sciences, Inc.
$66
Puma Biotechnology, Inc.
$65
Pharmacyclics LLC, An AbbVie Company
$65
Jazz Pharmaceuticals Inc.
$48
GENZYME CORPORATION
$46
Regeneron Healthcare Solutions, Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$42
Octapharma USA, Inc.
$40
Emmaus Medical, Inc.
$37
Adaptive Biotechnologies Corporation
$35
Secura Bio, Inc.
$34
AVEO Pharmaceuticals, Inc.
$31
Sirtex Medical Inc
$29
ARRAY BIOPHARMA INC
$28
EMD Serono, Inc.
$27
Eisai Inc.
$27
Rigel Pharmaceuticals, Inc.
$26
Myovant Sciences Inc.
$22
Novocure Inc.
$21
Teva Pharmaceuticals USA, Inc.
$20
Blue Earth Diagnostics Limited
$17
Nestle HealthCare Nutrition Inc.
$16
Global Blood Therapeutics, Inc.
$15
JAZZ PHARMACEUTICALS INC.
$15
Merck Sharp & Dohme LLC
$14
Myriad Genetic Laboratories, Inc.
$14
Amarin Pharma Inc.
$14
TESARO, Inc.
$14
EISAI INC.
$14
Taiho Oncology, Inc.
$14
Sobi, Inc
$14
Pharmacyclics LLC, an AbbVie Company
$13
Mylan Institutional Inc.
$12
AbbVie Inc.
$12
Daiichi Sankyo Inc.
$11
Top 3 companies account for 31.4% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ALIMTA · Alecensa · Aliqopa · Axumin · BOSULIF · BRAFTOVI · CABLIVI · CABOMETYX · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELIQUIS · ELITEK · EMPLICITI · ERBITUX · Endari · Enhertu · Erleada · FARXIGA · FARYDAK · FOTIVDA · Farydak · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · INREBIC · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NINLARO · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Ogivri · Optune · Ozempic · PADCEV · PANZYGA · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RYDAPT · Revlimid · SIR-Spheres Microspheres · SPRYCEL · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TRELEGY ELLIPTA · TRULICITY · Tavalisse · Trodelvy · Truxima · VENCLEXTA · VOTRIENT · VYXEOS · Vascepa · Victoza · XALKORI · XOSPATA · XTANDI · ZEJULA · ZENPEP · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
741
County median income
$90,032
Nearest hospital to ZIP centroid (approximate)
JERSEY CITY MEDICAL CENTER
2.2 mi
2.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Badin is a mixed practice specialist, with above-average Medicare volume (top 20% in NJ), with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Badin experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Badin performed 26,839 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Badin receive payments from pharmaceutical companies?
Yes. Dr. Badin received a total of $5,683 from 55 companies across 313 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Badin's costs compare to other hematology & oncology specialists in Jersey City?
Dr. Badin's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Badin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jersey City
Browse hematology & oncology specialists in Jersey City ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology